Gut Microbial pharmacogenomics, AI, Pharmacogenetics, and “deep” data sets are transforming Drug Trials and Discovery.
Ranjan Sinha
Founder & CEO @ DIGBI HEALTH | Precision Biology - Genetics, Gut microbiome- Based Care for chronic lifestyle illnesses
Our #genes play a role in the metabolism of over 400 commonly prescribed and OTC drugs.
Over the last ten years, there has been compelling evidence that the #gutmicrobiome plays an equally, if not more significant, role in drug metabolism.
The gut microbiome not only produces bio-active anti-inflammatory, anti-obesity chemicals, hormones, and #neurotransmitters that act like drugs but actively participates in the metabolism of the drugs we consume. Human gut microorganisms metabolize 176 of 271 tested drugs, with activity varying between individuals, resulting in inactivation, activation, detoxification or re-toxification with activity varying between individuals. This bacterial activity manifests in poor or non-responders to a drug or individuals with adverse effects.
Digbi Health's #AI multi-omic platform "Farmacy to Pharmacy”? incorporates genetics, longitudinal diet, #medications , phenotype, microbiome data, and clinical signals to help advance care, cure, #drugdevelopment , trial design, and even #drugdiscovery .
诺和诺德 will begin a pilot project to evaluate how genomic and microbiome-based tests can be used to help prevent obesity. The work is part of a tie-up with Digbi Health and comes as Novo's #wegovy franchise is expected to keep up its quick growth.
References
Product Leader | DigitalHealth | HealthTech
1 年Congratulations on the exciting partnership with Novo Nordisk!
Healthcare Innovation I Advisory Board Member I Investor
1 年This is the game changer In connecting your biology to “food as medicine” with pharma to impact obesity, diabetes, mental health, and cardiac…congrats Ranjan!